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Abstract
While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging,
pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify and randomise
patients to experimental treatments. The use of pathological parameters as primary and secondary outcome mea-
sures, either as standalone classifiers or in combination with clinical data, is also becoming more common. More-
over, reporting of estimates of residual disease, termed ‘pathological complete response’, have been incorporated
into neoadjuvant clinical trials. Pathologists have the expertise to deliver this essential information and they also
understand the requirements and limitations of laboratory testing. Quality assurance of pathology-derived data
builds confidence around trial-specific findings and is necessarily focused on the reproducibility of pathological
data, including ‘estimates of uncertainty of measurement’, emphasising the importance of pathologist education,
training, calibration and demonstration of satisfactory inter-observer agreement. There are also opportunities to
validate objective image analysis tools alongside conventional histological assessments. The ever-expanding port-
folio of clinical trials will demand more pathologist engagement to deliver the reliable evidence-base required for
new treatments. We provide guidance for quality assurance of pathology scoring and reporting in clinical trials.
Keywords: pathology; clinical trials; quality assurance; immunohistochemistry; biomarkers
Received 24 July 2018; Revised 11 October 2018; Accepted 1 November 2018
No conflicts of interest were declared.
Introduction
A Quality Assurance in Clinical Trials Workshop was
convened by the UK National Cancer Research
Institute Cellular-Molecular Pathology Initiative
(NCRI CM-Path). The workshop was held on
21 March 2017 with representation from the UK Med-
icines and Healthcare products Regulatory Agency
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(MHRA), industry and pathology. Four subgroups
were formed to tackle issues around regulation: train-
ing: trial oversight: and scoring and reporting. The
subject areas were researched by the subgroup mem-
bers prior to the workshop and presented by the sub-
group leads for general discussion by the workshop
participants. This article provides an overview of the
discussions around scoring and reporting of pathology
parameters in clinical trials. Discussions around the
benefits and challenges in using digital pathology and
image analysis were wide-ranging and will therefore
be presented in a separate article. The workshop for-
mulated ‘practice points’ to help pathologists navigate
the development, set up and delivery of clinical trials
and these are placed in italics at the end of each
section and compiled in Table 1.
Scoring and reporting of pathology parameters is an
interpretive skill; consequently there is an acknowl-
edged subjective variation in clinical practice from
pathologist to pathologist, even within the same centre.
For clinical trials, the challenge is to control for varia-
tions in individual pathologist practice to limit the
introduction of bias and errors. Common pathology
parameters used in clinical trials include: diagnosis;
grading; staging; biomarker scoring; pathological com-
plete response (pCR); resection margins and
recurrence.
Diagnosis, grading and staging are routinely carried
out in clinical practice following well-established
guidelines (e.g. Royal College of Pathologists, College
of American Pathologists, Union for International Can-
cer Control, American Joint Committee on Cancer).
The information can be collected from participating
sites using a carefully designed ‘pathology case report
form’ (Pathology CRF). Central review of at least a
proportion of specimens is desirable for quality assur-
ance purposes, but the extent of review will depend on
the aims and objectives of the trial, diagnostic confi-
dence, reproducibility of grading schemes and the ease
of application of staging systems.
Immunohistochemistry, in situ hybridisation or
molecular profiling of tumours may be used for trial
entry, patient stratification and randomisation into
treatment arms. If a trial is multicentre, it must be con-
sidered whether testing will be carried out at the par-
ticipating sites or co-ordinated by a central laboratory.
Generally, it is preferable that biomarker testing is car-
ried out at the participating sites as they benefit from
proximity to patient care and this mitigates against
delays in the patient pathway. In the case where labo-
ratory tests are not generally available or are specia-
lised tests developed for the trial, then a central
laboratory with the requisite expertise and appropriate
level of accreditation is necessary to run the trial effec-
tively. It is important to consider realistic turnaround
times when considering central laboratory testing and
to manage the expectations of the participating sites
and trial co-ordinators. Trial sample logistics, labora-
tory capacity and likelihood of repeat tests need to be
considered. Whether tests are delivered at participating
sites or a central laboratory, quality assurance mea-
sures need to be considered and implemented.
It is well known that the results of laboratory tests
are influenced by a myriad of variables (Table 2) [1].
Pre-analytical variables are those associated with pres-
ervation and preparation of tissue prior to testing. Ana-
lytical variables are specific to the test carried out.
Post-analytical variables, particularly associated with
Table 1. Summary of scoring and reporting practice points
• Scoring and reporting should be carried out blinded to treatment
allocation and clinical outcomes.
• The effect of diagnostic drift and chronological bias should be
considered throughout the trial, in particular if scoring and reporting
is carried out over several years and/or if new reporting guidelines
are published.
• Double reporting and/or central review should be considered to
increase confidence in the pathology data.
• The formation of a ‘Pathology Working Group’ should be considered
to oversee the pathology aspects of a study.
• Training requirements for pathologists participating in clinical trials
need to be addressed and will depend on whether the parameter is
an established clinical test or a novel biomarker.
• Auto-stainers should be used for immunohistochemistry in
preference to manual staining.
• Staining should be carried out in an ISO15189:2012-accredited
laboratory or laboratory working to GCP standards and is mandatory
for primary or secondary endpoints of CTIMP clinical trials.
• Measures to assure confidence in the reproducibility of pathologist
scoring should be considered, for example, by reporting levels of
inter and intra-observer agreement.
• The pathologists in the trial should agree what is considered
background staining and thus filtered out of pathologist scoring and
this should be kept under review during the trial.
• Companion and complementary diagnostic tests should be used in
preference to laboratory-devised assays. Manufacturers’ instructions
must be followed to produce a reliable result.
• Estimates of uncertainty, defined in ISO 15189:2012, should be
made for clinical trial tests where possible.
• The requirement for pathologist calibration should be considered
prior to the trial opening.
• If an external quality assurance scheme (e.g. UK NEQAS ICC & ISH) is
available for the trial test then trial laboratories should participate.
• Clear definitions of reporting of pathological complete response and
SOPs for standardised assessment need to be agreed and established
prior to the trial opening.
• Pathologists should be actively involved in developing trial specific
bio-resources.
• Pathologists’ contributions to clinical trials are wide ranging and
should be recognised and appropriately funded.
• Early pathologist engagement and input into trial design is essential.
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immunohistochemistry, are a consequence of subjec-
tive assessment by the pathologist, which is at best
semi-quantitative, but variability can be estimated by
measuring the degree of inter-observer and intra-
observer agreement. Molecular testing of tissue
homogenates using ‘grind and bind’ techniques benefit
from quantitative results, but each specific assay has
characteristic technical challenges and they lack the
morpho-molecular features of tests carried out on
intact tissue sections [2].
Pathology reporting in clinical trials
Ideally, assessment of pathology-based clinical trial
endpoints should be masked or blinded to randomisa-
tion and clinical outcomes. For exploratory outputs, a
staged approach may be more appropriate, such as that
proposed by the Society for Toxicological Pathology
[3]. The first stage is an un-blinded comparison of
treated and control specimens to identify consistent
changes and to develop scoring criteria. This strategy
facilitates identification of subtle, treatment related
findings that can be consistently differentiated from
those that occur in controls [4]. An independent
pathology peer review with targeted blinding may also
help minimise bias [5].
Scoring and reporting should be carried out blinded
to treatment allocation and clinical outcomes.
Diagnostic drift and chronological bias
Diagnostic drift and chronological bias should be con-
sidered when setting up a clinical trial. Diagnostic drift
is a gradual change in nomenclature, grading of
lesions, or scoring of a biomarker within a single study
over time. It is a source of inconsistency that can nega-
tively affect detection of treatment-related changes or
the determination of ‘no-effect’ levels [3]. Chronologi-
cal bias is defined as the evolutionary process of a
grading system, whereby more sensitive and specific
criteria for grade assignment are clarified, learned and
disseminated. As pathologists gain experience, subtle-
ties of the evolving system are applied to interpretation
of tissue sections [6]. This is also a source of inconsis-
tency that can negatively affect detection of treatment-
related changes or the determination of the ‘no-effect’
levels [4]. Plans for monitoring diagnostic drift and
chronological bias should be considered for trials pro-
jected to recruit over several years. Comparison of
pathology data at planned intervals throughout the life
of the study, for example at the beginning, middle and
end of the study, is recommended.
The effect of diagnostic drift and chronological bias
should be considered throughout the trial, in particular
if scoring and reporting is carried out over several
years and/or if new reporting guidelines are published.
Double reporting and central review
Double reporting to verify pathological parameters
such as diagnosis, grade, stage and biomarker scores is
recommended, but may not be feasible in real time.
Pathology review of cases should be considered as part
of the trial design. The extent of the review process
will depend on the number of cases, the complexity of
the scoring, and the contribution of pathology parame-
ters to the trial endpoints. Statistical advice should be
sought when designing the review strategy. Central
review by a lead pathologist or a group of pathologists
should be completed before final data analysis and trial
publication. For example, Speight et al (2015)
described a system for review of cases from patients
with oral epithelial dysplasia that involved four pathol-
ogists with adjudication of disagreements towards a
consensus diagnosis as the gold standard for clinical
Table 2. Pathology variables that may influence pathology scoring
and reporting of immunohistochemistry and in situ
hybridisation [1]
Variable Description Examples
Pre-analytical Tissue preservation Time to fixation, warm and cold
ischaemia times
Type of fixative, concentration, pH,
temperature and duration
Size of sample versus volume of
fixative
Tissue processing Dehydration and clearing
schedules
Section preparation Section thickness, temperature
and duration of section drying
Fresh cut sections versus stored
sections versus paraffin wax
‘dipped’ sections
Block storage Temperature and duration of block
storage
Analytical Laboratory test Type of proprietary auto-stainer
Tissue conditioning, unmasking
reagents, pH, temperature and
incubation time
Blocking reagent
Primary antibody, concentration,
incubation time
Detection system
Post-analytical Pathologist Experience
Specialist reporting
Biomarker scoring training and
accreditation
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trials [7]. Central pathology review may be ‘blinded’,
meaning independent assessment without knowledge
of the participating site data or ‘un-blinded’ where the
original pathology report or pathology CRF is
available and data are simply checked for any
disagreements.
Double reporting and/or central review should be con-
sidered to increase confidence in the pathology data.
Pathology working groups
Pathology working groups have been used in some tri-
als to good effect. For example, ProtecT (Prostate
Testing for Cancer and Treatment), a randomised con-
trolled trial comparing active monitoring, radiotherapy
and radical prostatectomy in patients with localised
prostate cancer, employed a Pathology Working Group
that oversaw the pathology aspects of the trial and
published impactful pathology-specific papers from
the trial [8,9]. Such groups enhance the quality of a
study by actively engaging pathologists in the devel-
opment of trial protocols, providing training, formulat-
ing pathology standard operating procedures (SOPs),
conducting central review, resolving discrepancies and
disseminating the trial findings to the pathology
community.
The formation of a ‘Pathology Working Group’ should
be considered to oversee the pathology aspects of a
study.
Providing quality assured pathology tests
To ensure that pathology laboratory tests are scored
and reported in a consistent manner it is recommended
that a systematic process is established comprising, in
sequence, education, training and calibration.
Education and training
Pathologists are most likely to be asked to provide
immunohistochemistry-based tests for clinical trials.
Such tests may form part of the recommended datasets
for the histopathological reporting of cancer, in which
case the expertise is likely to be already established,
for example the scoring of oestrogen and HER2 recep-
tors in breast cancer [10,11]. Furthermore, they are
likely to be supported by external quality assurance
programmes (Table 3) [12]. For novel biomarkers,
where expertise is not established, it is essential that
participating pathologists understand the clinical con-
text of the test and the role of the test in the trial;
screening, recruitment, stratification or randomisation.
Knowledge of the performance characteristics of the
test is essential in order to recognise sub-optimal tests.
For example, assessment of external analyte controls
(same-slide based proprietary cell line controls or char-
acterised tissue controls) and review of expected stain-
ing of internal controls are required before scoring the
tumour. Trial-specific training may be delivered by
face-to-face site meetings, establishing trial-specific
pathology working groups or using on-line training
modules [13]. Such meetings can also be used to col-
lect feedback from the participating pathologists on
the SOPs associated with tissue collection, processing,
staining and scoring. In some circumstances, particu-
larly with more complex SOPs, it is best practise to
run trial-specific protocols, prior to the trial opening,
to identify any operational problems.
Training requirements for pathologists participating
in clinical trials need to be addressed and will depend
on whether the parameter is an established clinical
test or a novel biomarker.
Immunohistochemistry
Guidance on validation of immunohistochemistry
assays in a clinical service is already available [14].
This guidance can be followed when incorporating
immunohistochemistry into a clinical trial. The assay
must be assessed for accuracy and analytical sensitiv-
ity/specificity. Once validation is completed, the assay
should be regularly monitored and performance
against known external positive controls assessed [14].
In the UK, in the setting of a clinical trial, if immuno-
histochemistry forms part of the primary or secondary
outcomes, then this must be performed to a standard
to satisfy the MHRA, who inspect laboratories
Table 3. United Kingdom National External Quality Assessment
Service for immunohistochemistry and in situ hybridisation
(UK NEQAS ICC & ISH) quality assurance modules for
immunocytochemistry [12]
Disease Test Drug
Breast cancer Oestrogen receptors
Progesterone receptors
HER2
Tamoxifen
Aromatase inhibitors
Trastuzumab
Gastric cancer HER2 Trastuzumab
Alimentary tract – Lynch
syndrome
MLH1, PMS2
MSH2, MSH6
Not applicable
Alimentary tract –
Gastrointestinal
stromal tumour (GIST)
CD117 (c-Kit), DOG-1 Imatinib
Non-small cell lung
cancer
ALK
PD-L1 (pilot scheme)
Crizotinib
Nivolumab
Pembrolizamab
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undertaking laboratory work for Clinical Trial of an
Investigational Medicinal Product (CTIMP) trials.
Immunohistochemistry can be performed manually or
on a proprietary automated stainer (auto-stainer). The
latter produce highly reliable tests and should be used
in preference to manual staining. Ideally, clinical trial
tests should be carried out in an ISO15189:
2012-accredited laboratory or a laboratory working to
Good Clinical Practice (GCP) standards. Such strin-
gency may not be required for exploratory tests, where
biomarker development is the aim.
Auto-stainers should be used for immunohistochemis-
try in preference to manual staining.
Staining should be carried out in an ISO15189:
2012-accredited laboratory or laboratory working to
GCP standards and is mandatory for primary or second-
ary endpoints of CTIMP clinical trials.
Scoring of immunohistochemistry
Numerous scoring methods have been devised for the
assessment of immunohistochemical staining. The
majority are based on the assessment of two parame-
ters: intensity of the staining and proportion of the
tumour that is stained (Table 4) [15]. Occasionally the
scoring system includes an assessment of the tumour
and the immune cells; an example is PD-L1 testing in
non-small cell lung cancer [16]. Scoring systems asso-
ciated with recognised predictive and prognostic
markers should be scored according to guidelines
[10,11,17]. For exploratory tests, researchers should
investigate the literature and implement validated scor-
ing systems or devise a scoring system to adequately
capture the data and to facilitate the development of
clinically relevant ‘cut-offs’. Tumour heterogeneity is
recognised as an important variable and needs to be
considered when devising scoring systems. Whilst it is
recognised that pathologist scoring is semi-quantitative
and subjective, measurement of inter-observer and
intra-observer agreement provides evidence of the
reproducibility of the scoring system and increases the
degree of confidence in the data [18]. For example, a
study that examined Ki-67 (MIB-1) scoring across
eight laboratories and a central reference laboratory
demonstrated high intra-laboratory reproducibility
(intraclass correlation = 0.94; 95% CI 0.93–0.97), but
only moderate inter-laboratory reproducibility (intra-
class correlation = 0.71, 95% CI = 0.47–0.78). Factors
contributing to inter-laboratory discordance were
tumour region selection, counting method and subjec-
tive assessment of staining positivity. Formal counting
methods gave more consistent results than visual
estimation [19]. There is considerable interest and
investment in developing quantitative image analysis
for scoring immunohistochemistry [1].
Measures to assure confidence in the reproducibility of
pathologist scoring should be considered, for example by
reporting levels of inter and intra-observer agreement.
Filtering
Individual pathologists have different thresholds for
observing and recording incidental morphological
changes, background staining or unexpected staining
patterns, called filtering. Recording such data, particu-
larly for novel biomarkers, may be important as the
information contributes to an understanding of the
characteristics of a particular test and informs bio-
marker development and refinement.
The pathologists in the trial should agree what is con-
sidered background staining, and thus filtered out of
pathologist scoring, and this should be kept under
review during the trial.
Companion and complementary diagnostic tests
Increasingly, the development of new drugs requires
specific diagnostic tests to guide treatment, called
companion and complementary diagnostic tests. Com-
panion tests are mandatory prior to administering a tar-
geted drug, whereas complementary tests are used to
guide patient selection for treatment, but are not used
as ‘gate-keepers’ for access to the drug. The rationale
Table 4. Scoring systems for immunohistochemistry [15]
Scoring
method
Intensity
score (IS)
Proportion
score (PS/%) Calculation
H score 0, 1, 2, 3 0–100%
(continuous)
H score = (1 × %IS1) + (2
× %IS2) + (3 × %IS3)
Range 0–300
Allred score 0, 1, 2, 3 1 = <1
2 = 1–10
3 = 10–33
4 = 33–66
5 = >66
Allred score = IS + PS
Range 0, 2–8
Additive quick
score
0, 1, 2, 3 1 = 0–4
2 = 5–19
3 = 20–39
4 = 40–59
5 = 60–79
6 = 80–100
Additive quick score = IS +
PS
Range 0–9
Multiplicative
quick score
0, 1, 2, 3 1 = 0–4
2 = 5–19
3 = 20–39
4 = 40–59
5 = 60–79
6 = 80–100
Multiplicative quick score =
IS × PS
Range 0–18
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for recommending such tests is based on the principle
of precision medicine: delivering the right drug to the
right patient at the right time, but is also driven by the
requirements of regulatory bodies such as the US FDA
and the UK MHRA. The paradigm for companion test-
ing is breast cancer where HER2 receptor testing
(e.g. HercepTest, Agilent Dako, Glostrup, Denmark) is
required prior to treatment with Trastuzumab. Such
diagnostic tests are manufactured to high standards and
satisfy the requirements for an in vitro diagnostic (IVD)
medical device, accredited by regulatory bodies. Fur-
thermore, UK National External Quality Assurance
Scheme (NEQAS) immunocytochemistry (ICC) and in
situ hybridisation (ISH) have shown that laboratories
using IVD tests outperform those using laboratory
developed assays [20]. One of the issues around the use
of IVDs is that the tests tend to be expensive and the
manufacturers’ instructions need to be followed pre-
cisely to produce a valid test result. Typically, the
instructions specify the use of a specific proprietary
auto-stainer, which may not be available in participating
laboratories. The problem can be resolved by setting up
central laboratory testing at a site with the designated
staining platform that can deliver quality assured tests.
Companion and complementary diagnostic tests
should be used in preference to laboratory-devised
assays. Manufacturers’ instructions must be followed
to produce a reliable result.
Estimates of uncertainty
Scoring immunohistochemistry may be subject to
‘estimates of uncertainty of measurement’. ISO
15189:2012 states that ‘the laboratory shall at least
attempt to identify all the components of uncertainty
and make a reasonable estimation, and shall ensure
that the form of reporting of the result does not give
the wrong impression of uncertainty’. This applies to
numerical counts of immunohistochemically positive
cells and working examples are provided in guidelines
provided by the UK Royal College of Pathologists
[21]. The recommendations include consideration of
the best methods to achieve clinically reliable mea-
surements, ensuring that these are defined in SOPs and
working to ensure that the measurement procedures
are consistent between pathologists [21].
Estimates of uncertainty, defined in ISO 15189:2012,
should be made for clinical trial tests where possible.
Calibration
It may be necessary to calibrate the laboratories and
pathologists prior to opening a trial. This can be
achieved by providing a ‘test set’ of cases and compil-
ing the results across the centres and providing feed-
back. This can be an iterative process aimed at
achieving a pre-specified level of performance or more
formal accreditation of the laboratory for the trial.
Typically, accredited laboratories would have high
levels of agreement with a reference laboratory or
demonstrate high levels of agreement with other labo-
ratories taking part in the trial. Statistical tests, such as
Cohen’s Kappa coefficient (ĸ) [22] or intraclass corre-
lation coefficient, can be used to measure inter-
laboratory or inter-observer agreement. In the case of
Cohen’s Kappa coefficient to assess categorical vari-
ables, the acceptable level of agreement is controver-
sial. Some researchers consider a ĸ of >0.6 (moderate
agreement) acceptable, whereas others stipulate a ĸ of
>0.8 (strong agreement) [22]. A statistician should be
consulted for advice on the most appropriate statistical
tests to use. Ideally, the statistician should analyse the
data independently of the pathologist(s) to ensure
objective assessment.
The requirement for pathologist calibration should be
considered prior to the trial opening.
External quality assurance
For established biomarkers, where external quality
assurance programmes already exist (e.g. UK NEQAS
for ICC and ISH), trial laboratories should participate
in such schemes and demonstrate satisfactory perfor-
mance (Table 3) [12].
If an external quality assurance scheme (e.g. UK
NEQAS ICC & ISH) is available for the trial test then
trial laboratories should participate.
Genomic testing
Factors such as acceptable testing platforms, nucleic
acid extraction kits, modality of testing and the thresh-
olds for positive results need to be set out in SOPs.
Fresh-frozen tissue is the gold standard for techniques
where nucleic acid quality requirements are high, for
example whole genome sequencing. Formalin-fixed
paraffin-embedded samples may be acceptable but are
subject to the numerous pre-analytical variables listed
in Table 2 [1,23]. If an external quality assurance
scheme for example, the UK NEQAS Molecular
Genetics programme exists for a particular test, then
laboratories should participate [24]. Pathologists
should review trial-specific patient information sheets
and consent forms to ensure that laboratory tests
6 M Robinson et al
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relating to germline mutations are disclosed and that
the participant understands the consequence of a posi-
tive result and the implications for family members.
Pathological complete response
Pathological estimates of residual disease following
trial-specific interventions, termed ‘pathological com-
plete response’, are being utilised to expedite the
reporting of clinical trials, where previously only
extended clinical follow up has been used [25–28]. It
is important that the participating pathologists have an
understanding of the definition of pCR; for example in
breast cancer trials, variable definitions have been used
allowing or excluding ductal carcinoma in situ from
the definition, which influences trial outcomes [29].
Nevertheless, central pathology review of a phase
3 neoadjuvant breast cancer trial (ARTemis) has
shown good concordance of pCR with participating
centre assessment, even in the absence of guidelines
and a trial-specific reporting proforma [30]. For colo-
rectal cancer, the UK Royal College of Pathologists
reporting guidelines specify that the entire scar should
be embedded and three deeper levels cut on each
block prior to calling a pCR. These principles should
be followed in trials and it is recommended that all
pCR cases are centrally reviewed. It is also important
to specify whether residual nodal disease should con-
tribute to pCR, as assessment of mesorectal lymph
nodes has been shown to reduce the rate of pCR [31].
Detailed SOPs are required to standardise block selec-
tion and sectioning protocols to ensure consistent
assessment of patient specimens across the trial sites
[26]. Similar principles can be applied to other mor-
phological parameters such as defining and measuring
resection margins in surgical trials and processing sen-
tinel lymph node specimens.
Clear definitions of reporting of pathological complete
response and SOPs for standardised assessment need to
be agreed and established prior to the trial opening.
Bio-resource for translational research
Tissue collected and curated as part of a clinical trial
(frozen tissue and/or formalin-fixed paraffin-embedded
tissue) is associated with high quality clinical data and
pathological classification. Consequently, it is an
important legacy that can be used for translational
research; for example, the tissue can be used to
develop and refine predictive tests. At trial inception,
pathologists should actively promote tissue collection
and incorporate the costs into the trial grant applica-
tion or formulate applications for a companion study.
The trial documentation, specifically the consent form
and patient information sheet, must be worded appro-
priately. If samples are to be kept beyond the end of
the trial, then consent needs to be enduring and ideally
generic. Samples may be moved into a biobank with
the correct consent provisions, ensuring that the rele-
vant regulations are followed; for example, in
England, tissue must be moved under an Human Tis-
sue Authority (HTA) licence and meet HTA standards
when the research ethics approval for the study
expires.
Pathologists should be actively involved in developing
trial specific bio-resources.
Conclusion
Our Quality Assurance in Clinical Trials Workshop
highlighted the importance of ensuring reproducible
scoring and reporting of pathology parameters in clini-
cal trials. Key considerations include pathologist train-
ing and calibration, and measurement of inter-observer
variation. There are opportunities to evaluate image
analysis systems in clinical trials, alongside conven-
tional histological assessment, to moderate ‘uncer-
tainty of measurement’. In any case, pathologists’
engagement in clinical trials is essential to help deliver
the reliable evidence-base required for new treatments
and robust pathology processes are vital to the credi-
bility of studies.
Pathologists’ contributions to clinical trials are wide
ranging and should be recognised and appropriately
funded.
Early pathologist engagement and input into trial
design is essential.
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